Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.

This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of romiplostim for the treatment of adults with chronic immune or idiopathic thrombocytopenic purpura (ITP) based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's evidence came from two relatively high-quality randomised controlled trials (RCTs). The ERG found no evidence that any important data were missed or that data extraction was inaccurate. In both RCTs more patients in the romiplostim than in the placebo group achieved a durable platelet response [non-splenectomised patients: romiplostim 25/41 (61%), placebo 1/21 (5%), odds ratio (OR) 24.45, 95% confidence interval (CI) 3.34 to 179.18; splenectomised patients: romiplostim 16/42 (38%), placebo 0/21 (0%), OR 8.5 (95% CI 1.15 to 372)] and an overall platelet response [non-splenectomised patients: romiplostim 36/41 (88%), placebo 3/21 (14%), OR 34.74, 95% CI 7.77 to 155.38; splenectomised patients: romiplostim 33/42 (79%), placebo 0/21 (0%), OR 16.6 (95% CI 2.37 to 706]. The difference in mean period with a platelet response was 13.9 weeks (95% CI 10.5 to 17.4) in favour of romiplostim in the RCT of non-splectomised patients and 12.1 weeks (95% CI 8.7 to 15.6) in favour of romiplostim in the RCT of splectomised patients. The manufacturer's economic model evaluated the cost-effectiveness of romiplostim compared with standard care. The ERG had concerns about the way the decision problem was addressed in the economic model and about the non-adjustment of findings for confounding factors. In non-splenectomised patients, using romiplostim as a first option treatment, the base-case incremental cost-effectiveness ratio (ICER) was 14,840 pounds per quality-adjusted life-year (QALY). In splenectomised patients the ICER was 14,655 pounds per QALY. Additional sensitivity analyses performed by the ERG identified two issues of importance: whether individuals entered the model on watch and rescue or on active therapy in the comparator arm (ICER 21,674 pounds per QALY for non-splenectomised patients, 29,771 pounds per QALY for splenectomised patients); whether it was assumed that any unused medicine would be wasted. Combining all of the separate sensitivity analyses, and assuming that watch and rescue was not the first-line treatment, increased the ICERs further (non-splenectomised 37,290 pounds per QALY; splenectomised 131,017 pounds per QALY). In conclusion, the manufacturer's submission and additional work conducted by the ERG suggest that romiplostim has short-term efficacy for the treatment of ITP, but there is no robust evidence on long-term effectiveness or cost-effectiveness of romiplostim compared with relevant comparators.

[1]  J. Bernard,et al.  Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. , 2009, Scandinavian journal of haematology.

[2]  F. Goebel,et al.  Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. , 2009, Scandinavian journal of haematology.

[3]  R. Fanin,et al.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results , 2008, European journal of haematology.

[4]  R. Porcher,et al.  Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. , 2008, Blood.

[5]  E. Vellenga,et al.  EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY , 2008 .

[6]  R. Fanin,et al.  Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura , 2008, Haematologica.

[7]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[8]  S. Amadori,et al.  Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults , 2007, Haematologica.

[9]  赵红彬 Placebo , 2007 .

[10]  J. Bussel,et al.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. , 2007, The New England journal of medicine.

[11]  T. Nagasawa,et al.  A Phase 2 Open-Label, Sequential-Cohort, Dose-Escalation Study of AMG 531 in Japanese Patients with Chronic Immune Thrombocytopenic Purpura (ITP). , 2007 .

[12]  T. Guthrie,et al.  Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531 , 2007 .

[13]  J. Logie,et al.  Risk of Cataracts among Idiopathic Thrombocytopenic Purpura (ITP) Patients in the UK General Practice Research Database (GPRD). , 2007 .

[14]  R. Fanin,et al.  A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP , 2007 .

[15]  T. Robak,et al.  Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura. , 2007 .

[16]  A. Flahault,et al.  Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. , 2007, Journal of the American Academy of Dermatology.

[17]  A. Majluf-Cruz,et al.  Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis , 2007, Annals of Hematology.

[18]  J. Bussel,et al.  Immune thrombocytopenic purpura in adults , 2007, Current opinion in hematology.

[19]  T. Robak,et al.  Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura , 2007, Hematology.

[20]  A. Ho,et al.  Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab , 2007, Annals of Hematology.

[21]  Jian Wang,et al.  Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. , 2007, Journal of the National Cancer Institute.

[22]  A. Matzdorff,et al.  Treatment of chronic immune thrombocytopenic purpura: the patients’ perspective , 2007, European journal of haematology.

[23]  J. Bussel,et al.  Safety and tolerability of a novel chromatography‐based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura , 2007, American journal of hematology.

[24]  M. Erkurt,et al.  Retrospective Analysis of Patients with Idiopathic Thrombocytopenic Purpura from Eastern Anatolia , 2007, Medical Principles and Practice.

[25]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[26]  J. Bussel,et al.  Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura : 2-year update , 2006 .

[27]  J. Sierra,et al.  Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura. , 2006 .

[28]  J. Christal,et al.  An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura , 2006, British journal of haematology.

[29]  J. George,et al.  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. , 2006, The New England journal of medicine.

[30]  J. George Management of patients with refractory immune thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.

[31]  P. Cernelc,et al.  Cyclosporin A as an Immunosuppressive Treatment Modality for Patients with Refractory Autoimmune Thrombocytopenic Purpura after Splenectomy Failure , 2006, International journal of hematology.

[32]  M. Loh,et al.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. , 2006, Blood.

[33]  F. Peñalver,et al.  Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients , 2006, Annals of Hematology.

[34]  S. Golder,et al.  Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. , 2006, Health information and libraries journal.

[35]  R. Fanin,et al.  Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. , 2005, Experimental hematology.

[36]  J. George,et al.  Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura. , 2005 .

[37]  D. Case,et al.  Rituximab Produces Long-Term Responses in Immune Thrombocytopenic Purpura (ITP). , 2005 .

[38]  J. Vela-Ojeda,et al.  Treatment of Refractory Chronic Immune Thrombocytopaenic Purpura (ITP) with Rituximab: Report of a Cases Series. , 2005 .

[39]  B. George,et al.  Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients , 2005, European journal of haematology.

[40]  K. Ramadan,et al.  Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. , 2005, Clinical and laboratory haematology.

[41]  O. Lambotte,et al.  Efficacy of mycophenolate mofetil in adult refractory auto‐immune cytopenias: a single center preliminary study , 2005, European journal of haematology.

[42]  T. Plesner,et al.  Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura , 2005, American journal of hematology.

[43]  J. Bussel,et al.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.

[44]  Lei Zhang,et al.  Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases. , 2005, Chinese medical journal.

[45]  T. Guthrie,et al.  Rituximab Induces High Response Rate and Prolonged Remission in Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Retrospective Analysis. , 2004 .

[46]  I. Tabbara,et al.  The Use of Anti-CD20 Chimeric Monoclonal Antibody, Rituximab in Adult Patients with Treatment Refractory Immune Thrombocytopenia. , 2004 .

[47]  Chien-Feng Chen,et al.  An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP). , 2004 .

[48]  A. Jajeh,et al.  Rituximab in the Treatment of Adults with Chronic Idiopathic Thrombocytopenic Purpura (ITP) and Autoimmune Hemolytic Anemia (AIHA). , 2004 .

[49]  S. Vesely,et al.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. , 2004, Blood.

[50]  R. Mcmillan,et al.  Long-term outcomes in adults with chronic ITP after splenectomy failure. , 2004, Blood.

[51]  E. Andrès,et al.  Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. , 2004, The American journal of medicine.

[52]  E. Andrès,et al.  Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. , 2004, Clinical and laboratory haematology.

[53]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[54]  A. Canataroğlu,et al.  Anti-D and Intravenous Immunoglobulin Treatments in Chronic Idiopathic Thrombocytopenic Purpura. , 2004, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[55]  A. Angiolillo,et al.  IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life , 2004, Thrombosis and Haemostasis.

[56]  S. Vesely,et al.  Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy , 2004, Annals of Internal Medicine.

[57]  J. Penner,et al.  Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) , 2003, American journal of hematology.

[58]  T. Shanafelt,et al.  Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. , 2003, Mayo Clinic proceedings.

[59]  S. Vesely,et al.  Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care , 2003, American journal of hematology.

[60]  Shaji K. Kumar,et al.  Treatment advances in adult immune thrombocytopenic purpura , 2003, Annals of Hematology.

[61]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[62]  S. Proctor,et al.  Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients , 2003, British journal of haematology.

[63]  M. Hou,et al.  Mycophenolate mofetil (MMF) for the treatment of steroid‐resistant idiopathic thrombocytopenic purpura , 2003, European journal of haematology.

[64]  N. Xing,et al.  Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. , 2003, Blood.

[65]  W. Ouwehand,et al.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy , 2003, British journal of haematology.

[66]  P. Williams,et al.  Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies , 2003, Vox sanguinis.

[67]  U. Germing,et al.  Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study , 2002, European journal of haematology.

[68]  A. Tefferi,et al.  Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses , 2002, Annals of Hematology.

[69]  A. Hoffbrand,et al.  Mycophenolate mofetil for the treatment of refractory auto‐immune haemolytic anaemia and auto‐immune thrombocytopenia purpura , 2002, British journal of haematology.

[70]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[71]  J. Bussel,et al.  Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? , 2002, Blood.

[72]  R. Marasca,et al.  Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. , 2002, Blood.

[73]  S. Chevret,et al.  Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial , 2002, The Lancet.

[74]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[75]  M. V. van't Veer,et al.  Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy , 2001, British journal of haematology.

[76]  T. Dutta,et al.  Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults. , 2001, The Journal of the Association of Physicians of India.

[77]  J. Bussel,et al.  A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura , 2001 .

[78]  G. Dolan,et al.  Vigam‐S, a solvent/detergent‐treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura , 2001, Transfusion medicine.

[79]  J. Gutheil,et al.  A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. , 2000, Seminars in oncology.

[80]  S. Amadori,et al.  Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. , 2000, Blood cells, molecules & diseases.

[81]  B. Djulbegovic,et al.  The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. , 2000, Archives of internal medicine.

[82]  P. Bierling,et al.  Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. , 1999, British journal of haematology.

[83]  K. Schmidt,et al.  The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.

[84]  M. Goldaniga,et al.  ADULT REFRACTORY CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA: CAN DAPSONE BE PROPOSED AS SECOND‐LINE THERAPY? , 1999, British journal of haematology.

[85]  A D Oxman,et al.  The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials , 1998, BMJ.

[86]  D. Albayrak,et al.  Oral high‐dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura , 1997, American journal of hematology.

[87]  I. Reid Glucocorticoid osteoporosis--mechanisms and management. , 1997, European journal of endocrinology.

[88]  É. Oksenhendler,et al.  Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases , 1997, British journal of haematology.

[89]  J. Bussel,et al.  Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients , 1997 .

[90]  R. Mcmillan Therapy for Adults with Refractory Chronic Immune Thrombocytopenic Purpura , 1997, Annals of Internal Medicine.

[91]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[92]  G. Longo,et al.  Long‐term salvage treatment by cyclosporin in refractory autoimmune haematological disorders , 1996, British journal of haematology.

[93]  R. Espínola,et al.  [Treatment of idiopathic thrombocytopenic purpura with danazol]. , 1995, Sangre.

[94]  A. Perez,et al.  Dapsone for refractory chronic idiopathic thrombocytopenic purpura , 1995, British journal of haematology.

[95]  G. Papa,et al.  Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. , 1995, The American journal of medicine.

[96]  F. Rodeghiero,et al.  Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura , 1995, Annals of Hematology.

[97]  A. Reiner,et al.  Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. , 1995, Blood.

[98]  P. Bierling,et al.  Dapsone for idiopathic thrombocytopenic purpura , 1994, American journal of hematology.

[99]  P. Jacobs,et al.  Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. , 1994, The American journal of medicine.

[100]  E. Wattel,et al.  A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients , 1994, British journal of haematology.

[101]  D. Donovan Prospective or retrospective? , 1993, Journal of public health medicine.

[102]  F. Rodeghiero,et al.  Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. , 1993, Haematologica.

[103]  P. Bierling,et al.  Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. , 1993, Blood.

[104]  É. Oksenhendler,et al.  Dapsone for autoimmune thrombocytopenic purpura , 1993, American journal of hematology.

[105]  M. Ohto,et al.  Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy. , 1992, International journal of hematology.

[106]  F. Rodeghiero,et al.  A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. , 1992, Haematologica.

[107]  A. Manoharan Targeted‐immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia , 1991, Australian and New Zealand journal of medicine.

[108]  D. Meytes,et al.  Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura. , 1990, Postgraduate medical journal.

[109]  P. Fenaux,et al.  Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: A report on 43 cases , 1990, Blut.

[110]  J. Bussel,et al.  Alternation of two doses of intravenous gammaglobulin in the maintenance treatment of patients with immune thrombocytopenic purpura: More is not always better , 1990, American journal of hematology.

[111]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[112]  P. Fenaux,et al.  Re‐evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases , 1990, British journal of haematology.

[113]  R. Mylvaganam,et al.  Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. , 1989, The American journal of the medical sciences.

[114]  T. Baglin,et al.  The treatment of chronic idiopathic thrombocytopenia with anti-D (Rho) immunoglobulin: its effectiveness, safety and mechanism of action. , 1988, Clinical and laboratory haematology.

[115]  J. Bussel,et al.  Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. , 1988, Blood.

[116]  A. Manoharan Danazol therapy in patients with immune cytopenias. , 1987, Australian and New Zealand journal of medicine.

[117]  A. Avilés,et al.  Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). , 1987, Nouvelle revue francaise d'hematologie.

[118]  R. Coleman,et al.  Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. , 1987, The American journal of medicine.

[119]  P. Fenaux,et al.  The treatment of adult idiopathic thrombocytopenic purpura , 1987, European journal of haematology.

[120]  R. Mylvaganam,et al.  Low-dose danazol therapy in idiopathic thrombocytopenic purpura. , 1987, Annals of internal medicine.

[121]  P. Chien,et al.  Effect of danazol in immune thrombocytopenic purpura. , 1987, The New England journal of medicine.

[122]  A. Salama,et al.  Effect of IgG anti‐Rho(D) in adult patients with chronic autoimmune thrombocytopenia , 1986, American journal of hematology.

[123]  R. Clarke Nausea and vomiting. , 1986, British journal of anaesthesia.

[124]  A. Manoharan Slow infusion of vincristine in the treatment of idiopathic thrombocytopenic purpura , 1986, American journal of hematology.

[125]  B. Mcverry,et al.  The use of danazol in the management of chronic immune thrombocytopenic purpura , 1985, British journal of haematology.

[126]  M. Morales-Polanco,et al.  Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence. , 1985, Archivos de investigacion medica.

[127]  C. Bharucha,et al.  Fresh frozen plasma in the treatment of chronic autoimmune thrombocytopenic purpura in adults: evidence for potentiating effect of vincristine. , 1985, Clinical and laboratory haematology.

[128]  J. Pizzuto,et al.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.

[129]  J. Bergerat,et al.  High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults , 1984, Blut.

[130]  A. Salama,et al.  Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)) , 1984, Blut.

[131]  J. Akatsuka,et al.  A Cooperative Clinical Trial of High-Dose Immunoglobulin Therapy in 177 Cases of Idiopathic Thrombocytopenic Purpura , 1984, Thrombosis and Haemostasis.

[132]  J. Lewis,et al.  Intravenous gamma globulin in the treatment of chronic idiopathic thrombocytopenic purpura in adults. , 1984, The American journal of medicine.

[133]  W. Rosse,et al.  Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. , 1984, The American journal of medicine.

[134]  J. Lavery Rho(D) immune globulin. When to use it in the Rho(D)-negative woman. , 1984, Postgraduate medicine.

[135]  R. Mylvaganam,et al.  Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. , 1984, Annals of internal medicine.

[136]  J. Matsuda,et al.  Clinical effect of intravenous immunoglobulin on chronic idiopathic thrombocytopenic purpura , 1983, Blut.

[137]  A. Salama,et al.  EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA Competitive Inhibition of Reticuloendothelial System Function by Sequestration of Autologous Red Blood Cells? , 1983, The Lancet.

[138]  R. Mylvaganam,et al.  Danazol for the treatment of idiopathic thrombocytopenic purpura. , 1983, The New England journal of medicine.

[139]  A. Newland,et al.  HIGH-DOSE INTRAVENOUS IgG IN ADULTS WITH AUTOIMMUNE THROMBOCYTOPENIA , 1983, The Lancet.

[140]  Kueh Yk Vincristine therapy in refractory chronic idiopathic thrombocytopenic purpura. , 1982 .

[141]  T. Wong,et al.  The reversible binding of vinblastine to platelets: implications for therapy. , 1981, Blood.

[142]  V. Picozzi,et al.  Fate of therapy failures in adult idiopathic thrombocytopenic purpura. , 1980, The American journal of medicine.

[143]  E. Montserrat,et al.  Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. , 1980, Postgraduate medical journal.

[144]  S. Boonpucknavig,et al.  Chronic immunologic thrombocytopenic purpura: results of cyclophosphamide therapy before splenectomy. , 1980, Archives of internal medicine.

[145]  D. Mohanty,et al.  Idiopathic thrombocytopenic purpura (I.T.P.); clinico-pathological study of 30 cases. , 1979, The Journal of the Association of Physicians of India.

[146]  Deborah S. Smith,et al.  The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. , 1978, The New England journal of medicine.

[147]  J. Child,et al.  Responses to cinvristine in refractory idiopathic thrombocytopenic purpura. , 1976, British medical journal.

[148]  Y. Ahn,et al.  Vincristine therapy of idiopathic and secondary thrombocytopenias. , 1974, The New England journal of medicine.

[149]  E. Damasio,et al.  Vinblastine sulphate in idiopathic thrombocytopenic purpura. , 1971, Lancet.

[150]  R. Laros,et al.  "Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide. , 1971, JAMA.

[151]  T. Makino,et al.  [Refractory idiopathic thrombocytopenic purpura]. , 1969, Naika. Internal medicine.

[152]  B. Bouroncle,et al.  Treatment of refractory idiopathic thrombocytopenic purpura. , 1968, JAMA.

[153]  L. Sussman Azathioprine in refractory idiopathic thrombocytopenic purpura. , 1967, JAMA.

[154]  C. Corley,et al.  Azathioprine therapy of "autoimmune" diseases. , 1966, The American journal of medicine.

[155]  M. Baldini Idiopathic thrombocytopenic purpura. , 1966, The New England journal of medicine.

[156]  V. Preedy,et al.  Effect of 4-Week Heartfulness Meditation on Stress Scores, Sleep Quality, and Oxidative and Inflammatory Biochemical Parameters in COVID-19 Patients after Completion of Standard Treatment – A Randomized Controlled Trial , 2022, International journal of yoga.

[157]  Zeping Zhou,et al.  Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. , 2008, Critical reviews in oncology/hematology.

[158]  T. Taube,et al.  Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. , 2005, Haematologica.

[159]  D. Cines,et al.  Management of adult idiopathic thrombocytopenic purpura. , 2005, Annual review of medicine.

[160]  A. Mehta,et al.  Rituximab in the treatment of refractory autoimmune cytopenias in adults. , 2005, Haematologica.

[161]  C. Mueller-Eckhardt,et al.  High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP) clinical effects , 2004, Blut.

[162]  A. Bogdanović,et al.  Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. , 2003, The hematology journal : the official journal of the European Haematology Association.

[163]  R. Fanin,et al.  B-cell compartment as the selective target for the treatment of immune thrombocytopenias. , 2003, Haematologica.

[164]  G. Gutiérrez-Espíndola,et al.  High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. , 2003, Archives of medical research.

[165]  R. Fanin,et al.  B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.

[166]  S. Tura,et al.  Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. , 2001, Haematologica.

[167]  Shaji K. Kumar,et al.  Splenectomy for adult immune thrombocytopenio purpura and treatment of post-splenectomy relapses , 2000 .

[168]  U. Coşkun,et al.  Long Term Follow-Up of 26 Patients With Adult Idiopathic Thrombocytopenic Purpura , 1999 .

[169]  O. Samoilova,et al.  [Treatment of idiopathic thrombocytopenic purpura in adults: efficacy of domestic intravenous immunoglobulin in immune thrombocytopenia]. , 1999, Terapevticheskii arkhiv.

[170]  Aksenov Av,et al.  Movalis treatment of low back pain (LBP) , 1999 .

[171]  A. Eldor,et al.  Clinical and Therapeutic Experience in 712 Israeli Patients with Idiopathic Thrombocytopenic Purpura , 1994 .

[172]  T. Barbui,et al.  High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. , 1991, Blood.

[173]  P. Fenaux,et al.  The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases. , 1990, Nouvelle revue francaise d'hematologie.

[174]  S. Asano,et al.  Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. , 1990, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[175]  W. Tyminski,et al.  [Use of vincristine-loaded blood platelets, danazol and gamma globulin in the treatment of patients with idiopathic thrombocytopenic purpura]. , 1989, Acta haematologica Polonica.

[176]  M. Linares,et al.  Slow infusion of vincristine in the treatment of refractory thrombocytopenic purpura. , 1988, Acta haematologica.

[177]  E. Ascari,et al.  Danazol therapy for idiopathic thrombocytopenic purpura (ITP). , 1988, Haematologica.

[178]  M. Podolak-Dawidziak,et al.  Danazol in chronic idiopathic thrombocytopenic purpura resistant to corticosteroids. , 1987, Folia haematologica.

[179]  M. Mazzucconi,et al.  Danazol therapy in refractory chronic immune thrombocytopenic purpura. , 1987, Acta haematologica.

[180]  D. Almagro Danazol in idiopathic thrombocytopenic purpura. , 1985, Acta haematologica.

[181]  T. Barbui,et al.  Danazol for the treatment of idiopathic thrombocytopenic purpura. , 1985, Acta haematologica.

[182]  S. Tarui,et al.  High-dose gammaglobulin therapy for idiopathic thrombocytopenic purpura in adults. , 1983, Acta haematologica.

[183]  R. Laros,et al.  Treatment of refractory thrombocytopenic purpura with cyclophosphamide , 1976, American journal of hematology.